Close Menu

Biocartis

The combination of the new test with Biocartis' existing KRAS assay offers customers a complete solution for testing metastatic colorectal cancers as reccomended by professional guidelines.

The firm offered a qualitative assessment of third quarter business activities, and announced a private placement and a US distribution deal with Thermo Fisher.

The funding will support manufacturing of the firm's Idylla PCR-based diagnostics platform and worker training at its Mechelen, Belgium facility.

An expansion of its oncology test menu helped drive installations of its Idylla molecular diagnostics system and cartridge sales in the first half of 2016.

Assessments of the firm's rapid molecular BRAF and EGFR tests by researchers in Italy and South Korea showed high sensitivity and a fast turnaround time.

The Belgian molecular diagnostics company said it will focus on expanding its capability to manufacture its Idylla diagnostics.

Researchers also found that higher frequencies of BRAF V600E mutations in the blood were associated with poorer outcomes and less responsiveness to BRAF inhibitors.

The spike in collaboration revenue offset a drop in product revenue while the firm anticipates several key regulatory approvals in the coming year.

The tests analyze tumor samples for mutations oncogenes including KRAS and NRAS in order to help guide treatment decisions for patients with metastatic colorectal cancer.

The new test will be based on Biocartis' Idylla PCR-based diagnostics platform and will detect an extended panel of RAS mutations, plus BRAF V600 mutations.

Pages

The New York Times looks at companies using genomic tools to try to quickly identify the cause of patients' infections.

The White House has asked for $2.5 billion in funding to address the COVID-19 outbreak, according to the Associated Press.

A resignation at the Marine Biological Laboratory highlights that institutions are unsure of how to handle researchers previously found to have violated codes of conduct, Nature News says.

In PNAS this week: immune responses that affect heart transplant rejection risk, gene variants associated with thiopurine toxicity, and more.